MORRIS PLAINS, N.J., Oct. 25, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that an article published yesterday in Blood described a mechanism by which epratuzumab affects B cells. Epratuzumab is a humanized anti-CD22 antibody currently in Phase III trials conducted by the Company's corporate partner, UCB (Euronext Brussels:UCB), as a therapeutic for patients with systemic lupus erythematosus (lupus).
The article was authored by several scientists of the Company, as well as a clinical collaborator, Dr. Daniel J. Wallace of Cedars-Sinai Medical Center of UCLA in Los Angeles, CA. The article was featured on the cover of this issue of Blood with a fluorescence microscopy image, showing how epratuzumab can translocate certain surface proteins on B cells to other blood cells, a process called trogocytosis.
Accompanying the article was an invited commentary by Dr. Ronald P. Taylor of the University of Virginia School of Medicine, who is a pioneer on studies of trogocytosis involving anti-B-cell antibodies, such as rituximab.In the article by Rossi and colleagues of Immunomedics, it was demonstrated that epratuzumab can induce trogocytosis of CD22, CD21, CD19, and several other B-cell surface molecules from lymphocytes to other blood cells, such as monocytes, natural killer cells, and granulocytes. Epratuzumab is distinct from other B-cell antibodies, such as rituximab, because it does not drastically deplete B cells, but instead compromises B-cell autoimmune activity. The Immunomedics scientists postulated that removal of CD22, CD19, CD21 and other proteins from the surface of B cells reduces the autoimmune activity of these cells. In fact, B cells obtained from lupus patients who were treated with epratuzumab showed reduced CD22, CD19 and CD21. The authors suggest that this modulation of B cells via trogocytosis could be the major mechanism of epratuzumab in patients with lupus.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV